CST3 and chronic obstructive pulmonary disease: Plasma cathepsin S and cathepsin S/cystatin C ratios may be clinically useful biomarkers to discriminate susceptible individuals from nonsusceptible ones and asthmatics prior to development of airflow limitation in COPD.